Cargando…
MiR-126-Loaded Immunoliposomes against Vascular Endothelial Inflammation In Vitro and Vivo Evaluation
Due to the accompaniment of vascular endothelial inflammation during the occurrence and development of cardiovascular diseases (CVD), treatment modalities against vascular endothelial inflammation have been intensively investigated for CVD prevention and/or treatment. Vascular cell adhesion molecule...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221669/ https://www.ncbi.nlm.nih.gov/pubmed/37242620 http://dx.doi.org/10.3390/pharmaceutics15051379 |
_version_ | 1785049511482097664 |
---|---|
author | Tang, Yongyu Chen, Ying Guo, Qianqian Zhang, Lidan Liu, Huanhuan Wang, Sibu Wu, Xingjie Shen, Xiangchun Tao, Ling |
author_facet | Tang, Yongyu Chen, Ying Guo, Qianqian Zhang, Lidan Liu, Huanhuan Wang, Sibu Wu, Xingjie Shen, Xiangchun Tao, Ling |
author_sort | Tang, Yongyu |
collection | PubMed |
description | Due to the accompaniment of vascular endothelial inflammation during the occurrence and development of cardiovascular diseases (CVD), treatment modalities against vascular endothelial inflammation have been intensively investigated for CVD prevention and/or treatment. Vascular cell adhesion molecule-1 (VCAM-1) is a typical transmembrane inflammatory protein specifically expressed by inflammatory vascular endothelial. By inhibiting VCAM-1 expression through the miR-126 mediated pathway, vascular endothelial inflammation can be efficiently relieved. Inspired by this, we developed a miR-126-loaded immunoliposome with VCAM-1 monoclonal antibody (VCAM(ab)) decorated at its surface. This immunoliposome can be directly targeted to VCAM-1 at the inflammatory vascular endothelial membrane surface and achieve highly efficient treatment against inflammation response. The cellular experiment results showed the immunoliposome had a higher uptake rate towards inflammatory human vein endothelial cells (HUVECs) and can significantly downregulate the VCAM-1 expression level of inflammatory HUVECs. In vivo investigation further demonstrated that this immunoliposome displayed a higher accumulation rate at vascular inflammatory dysfunction sites than its non-VCAM(ab)-modified counterpart. These results suggest that this novel nanoplatform can effectively deliver miR-126 to vascular inflammatory endothelium, opening a new avenue for the safe and effective delivery of miRNA for potential clinical application. |
format | Online Article Text |
id | pubmed-10221669 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102216692023-05-28 MiR-126-Loaded Immunoliposomes against Vascular Endothelial Inflammation In Vitro and Vivo Evaluation Tang, Yongyu Chen, Ying Guo, Qianqian Zhang, Lidan Liu, Huanhuan Wang, Sibu Wu, Xingjie Shen, Xiangchun Tao, Ling Pharmaceutics Article Due to the accompaniment of vascular endothelial inflammation during the occurrence and development of cardiovascular diseases (CVD), treatment modalities against vascular endothelial inflammation have been intensively investigated for CVD prevention and/or treatment. Vascular cell adhesion molecule-1 (VCAM-1) is a typical transmembrane inflammatory protein specifically expressed by inflammatory vascular endothelial. By inhibiting VCAM-1 expression through the miR-126 mediated pathway, vascular endothelial inflammation can be efficiently relieved. Inspired by this, we developed a miR-126-loaded immunoliposome with VCAM-1 monoclonal antibody (VCAM(ab)) decorated at its surface. This immunoliposome can be directly targeted to VCAM-1 at the inflammatory vascular endothelial membrane surface and achieve highly efficient treatment against inflammation response. The cellular experiment results showed the immunoliposome had a higher uptake rate towards inflammatory human vein endothelial cells (HUVECs) and can significantly downregulate the VCAM-1 expression level of inflammatory HUVECs. In vivo investigation further demonstrated that this immunoliposome displayed a higher accumulation rate at vascular inflammatory dysfunction sites than its non-VCAM(ab)-modified counterpart. These results suggest that this novel nanoplatform can effectively deliver miR-126 to vascular inflammatory endothelium, opening a new avenue for the safe and effective delivery of miRNA for potential clinical application. MDPI 2023-04-30 /pmc/articles/PMC10221669/ /pubmed/37242620 http://dx.doi.org/10.3390/pharmaceutics15051379 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tang, Yongyu Chen, Ying Guo, Qianqian Zhang, Lidan Liu, Huanhuan Wang, Sibu Wu, Xingjie Shen, Xiangchun Tao, Ling MiR-126-Loaded Immunoliposomes against Vascular Endothelial Inflammation In Vitro and Vivo Evaluation |
title | MiR-126-Loaded Immunoliposomes against Vascular Endothelial Inflammation In Vitro and Vivo Evaluation |
title_full | MiR-126-Loaded Immunoliposomes against Vascular Endothelial Inflammation In Vitro and Vivo Evaluation |
title_fullStr | MiR-126-Loaded Immunoliposomes against Vascular Endothelial Inflammation In Vitro and Vivo Evaluation |
title_full_unstemmed | MiR-126-Loaded Immunoliposomes against Vascular Endothelial Inflammation In Vitro and Vivo Evaluation |
title_short | MiR-126-Loaded Immunoliposomes against Vascular Endothelial Inflammation In Vitro and Vivo Evaluation |
title_sort | mir-126-loaded immunoliposomes against vascular endothelial inflammation in vitro and vivo evaluation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221669/ https://www.ncbi.nlm.nih.gov/pubmed/37242620 http://dx.doi.org/10.3390/pharmaceutics15051379 |
work_keys_str_mv | AT tangyongyu mir126loadedimmunoliposomesagainstvascularendothelialinflammationinvitroandvivoevaluation AT chenying mir126loadedimmunoliposomesagainstvascularendothelialinflammationinvitroandvivoevaluation AT guoqianqian mir126loadedimmunoliposomesagainstvascularendothelialinflammationinvitroandvivoevaluation AT zhanglidan mir126loadedimmunoliposomesagainstvascularendothelialinflammationinvitroandvivoevaluation AT liuhuanhuan mir126loadedimmunoliposomesagainstvascularendothelialinflammationinvitroandvivoevaluation AT wangsibu mir126loadedimmunoliposomesagainstvascularendothelialinflammationinvitroandvivoevaluation AT wuxingjie mir126loadedimmunoliposomesagainstvascularendothelialinflammationinvitroandvivoevaluation AT shenxiangchun mir126loadedimmunoliposomesagainstvascularendothelialinflammationinvitroandvivoevaluation AT taoling mir126loadedimmunoliposomesagainstvascularendothelialinflammationinvitroandvivoevaluation |